Sunshine Biopharma (NASDAQ:SBFMW – Get Free Report) is projected to issue its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $10.00 million for the quarter.
Sunshine Biopharma Trading Up 10.0%
SBFMW traded up $0.02 during midday trading on Friday, reaching $0.17. 41 shares of the company’s stock traded hands, compared to its average volume of 1,533. Sunshine Biopharma has a 52 week low of $0.11 and a 52 week high of $0.98. The firm has a fifty day moving average of $0.17 and a two-hundred day moving average of $0.19.
About Sunshine Biopharma
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
Read More
- Five stocks we like better than Sunshine Biopharma
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Elon Musk’s $1 Quadrillion AI IPO
- America’s 1776 happening again
- Buy This Stock Now
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
